The Kcap Trading Blog

"Hedge Fund Style Investing For Your Own Individual Account"

My Photo
Name:

Follow the Kcap Trading Blog and it's experienced long/short Portfolio Management Team, move for move, for intraday trading decisions AS THEY HAPPEN.

**Ranked among the top 100 financial blogs by Blogshares.com**

IMPORTANT: Please read disclosure at the bottom of each post



Monday, August 22, 2005

Click Here To E-mail Comments

Oversold bounce may continue

The market is having an oversold bounce which is being led by the Semiconductors. Most of the other indexes seem to be coming along for the ride. Nothing has changed in the internals for us to alter our view that this is a rally without legs. However, the momentum juices can likely get flowing if we take out near-term overhead levels. A close at or around 2150 on the NASDAQ might be enough to create some follow through to 2170. This is a little higher than we were discussing in our earlier post today.

After carefully analyzing the action in the NASDAQ this morning we noticed a gap between 2150 and 2170. Gaps usually need to be filled irregardless of the prevailing trend. The oversold condition of this market combined with a close at or around 2150 may be all that is needed for a little momentum to kick in. However, unless the internals show improved character, a rally to 2170 would still not impress us in altering the established downtrend. We would look to scale out of some of our long positions into that kind of strength.

We have done some bargain hunting on specific stocks that we like who have recently been hit hard. Google (symbol: GOOG) still has a hangover from its secondary offering and Baidu (symbol: BIDU) is down over 50% from its high. We have slightly increased our exposure to these two names. We have also initiated a very small position in Merrill Lynch Biotech Holder (symbol: BBH). We believe that should the NASDAQ begin to rally to 2170, traders would be searching for beta away from technology. Panacos Pharma (symbol: PANC) may have reminded traders that Biotech is usually a good alternative to the traditional technology stocks when in search of beta.

___________________________________________________
The analysis, opinions and/or forecasts expressed on the Kcap Trading Blog (“KTB”) are for informational purposes only and should not be relied upon in making investment decisions. By using this site you agree that Kleiner Capital Management, LLC (“KCAP”) and its principals are not liable for any action you take or any decision you make in reliance on any content. Please be aware that there is no commitment by KCAP to update the KTB. Furthermore, there may be inconsistent timing and follow up (if any) of posts.
None of the information on KTB is considered individualized investment advice and should not be construed as a recommendation or solicitation to purchase any securities. Reliance on information provided on KTB in no way establishes an advisor-client relationship. Investors are encouraged to seek the advice of a qualified investment professional prior to investing funds.
Clients of KCAP, as well as the firm’s principals and other employees, may be invested in securities discussed at KTB. However, any mention of said securities is not intended to influence market conditions for the security to the benefit of KCAP clients and/or principals and employees. KCAP is not affiliated with any advertisers on this site and does not endorse any of their content. For additional information and disclosures, please visit www.kleinercapital.com.
The information on KTB has been furnished from sources we consider to be reliable, but no guarantee is made with respect to accuracy.

___________________________

Click Here To E-mail Comments



Google
 
Web Kcap Trading Blog